Cover Image
市場調查報告書

中國的慢性阻塞性肺病藥物市場:2016∼2020年

COPD Drugs Market in China 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 361558
出版日期 內容資訊 英文 74 Pages
訂單完成後即時交付
價格
Back to Top
中國的慢性阻塞性肺病藥物市場:2016∼2020年 COPD Drugs Market in China 2016-2020
出版日期: 2016年06月17日 內容資訊: 英文 74 Pages
簡介

大氣污染成為提高慢性阻塞性肺罹患率的重要因素。中國40多歲以上的人口有相當於近10%的人罹患慢性阻塞性肺病病。預計至2020年成為國內死因的第1名。全球中國的慢性阻塞性肺病藥物市場,預計2016∼2020年,以年複合成長率15.56%擴大。

本報告提供中國的慢性阻塞性肺病藥物市場現狀與2020年的預測,市場規模與銷售趨勢,彙整主要供應商的競爭環境與簡介。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 慢性阻塞性肺病:概要

  • 原因和風險因素
  • 徵兆
  • 診斷
  • 管理

第6章 中國:國內概要

  • 社會及經濟趨勢
  • 醫療改革
  • 醫療基礎設施

第7章 中國的醫藥品產業

  • 市場概要
  • 中國的大醫藥品供應商
  • 全球及國內供應商的機會
  • 中國的藥物認證流程

第8章 與藥價償付

第9章 產品研發線

第10章 全球呼吸系統用藥物市場

第11章 市場情況

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第12章 藥物類別市場區隔

  • 支氣管擴張劑
  • PDE-4抑制劑
  • 類固醇
  • 聯合治療
  • 其他

第13章 推動市場的要素

第14章 促進要素的影響

第16章 促進要素與課題的影響

第17章 市場趨勢

第18章 供應商環境

  • 競爭模式
  • AstraZeneca
  • Boehringer Ingelheim
  • GSK
  • Merck
  • Novartis
  • 其他值得注意的供應商

第19章 附錄

第20章 關於Technavio

目錄
Product Code: IRTNTR9585

About the Chronic Obstructive Pulmonary Disease (COPD) Drugs Market in China

Chronic obstructive pulmonary disease (COPD) is a broad term that covers progressive lung diseases, including emphysema, chronic bronchitis, refractory (non-reversible) asthma, and some forms of bronchiectasis. It restricts airflow in the lungs and is characterized by diffculty breathing. The exact etiology of COPD is not understood, but most cases are caused due to genetic factors and by inhaling pollutants, including smoke, fumes, and chemicals. As the disease develops, the symptoms tend to get worse and damages the lungs. The disease cannot be cured, and can only be managed and treated.

The COPD drugs market in China is under penetrated. It is dominated by fixed dose combinations of LABA/ICS. Air pollution is the major contributing factor for the growing prevalence of the disease. Nearly 10% of the population in the region who are over the age of 40 years has COPD. The disease is expected to become one of the leading causes of death in the country by 2020. Lack of awareness about the disease and its treatment options affects the growth of the market in this region.

Technavio's analysts forecast the chronic obstructive pulmonary disease drugs market in China to grow at a CAGR of 15.56% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the chronic obstructive pulmonary disease drugs market in China for 2016-2020. To calculate the market size, Technavio considers the revenue generated from the total consumption of the chronic obstructive pulmonary disease drugs globally. The report does not include revenue generated from the aftermarket service of the product.

The market is divided into the following segments based on drug class:

  • Bronchodilators
  • Phosphodiesterase-4 (PDE-4) inhibitors
  • Steroids
  • Combination therapies

Technavio's report, Chronic Obstructive Pulmonary Disease (COPD) Drugs Market in China 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AstraZeneca
  • Boehringer Ingelheim
  • GSK
  • Merck
  • Novartis

Other Prominent Vendors

  • Ache Laboratorios Farmaceuticos
  • Almirall
  • Aquinox Pharmaceuticals
  • Ario Pharma
  • BioMarck Pharmaceuticals
  • Gilead Sciences
  • Mereo BioPharma Group
  • Mylan
  • Orion
  • Pearl Therapeutics
  • Prosonix
  • Teva Pharmaceutical Industry
  • Theravance Biopharma
  • Theron Pharmaceuticals
  • Verona Pharma
  • Xention
  • ZAI Lab

Market driver

  • Increase in environmental pollution
  • For a full, detailed list, view our report

Market challenge

  • Low diagnosis rate
  • For a full, detailed list, view our report

Market trend

  • Increased focus on combination therapies
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: COPD: An overview

  • Causes and risk factors
  • Symptoms
  • Diagnosis
  • Management

PART 06: China-Country snapshot

  • Social and economic conditions
  • Healthcare reform
  • Healthcare infrastructure

PART 07: Pharmaceutical industry in China

  • Market overview
  • Major pharmaceutical vendors in China
  • Opportunities for global and local vendors
  • Drug approval process in China

PART 08: Drug pricing and reimbursement

  • Market-driven drug pricing strategy
  • Scrutinization of illegal pricing of drugs

PART 09: Pipeline portfolio

PART 10: Global respiratory drugs market

  • Market overview
  • Global COPD drugs market

PART 11: Market landscape

  • COPD drugs market in china
  • Five forces analysis

PART 12: Market segmentation by drug class

  • Bronchodilators
  • PDE-4 inhibitors
  • Steroids
  • Combination therapies
  • Other medications

PART 13: Market drivers

  • Increase in prevalence of smoking
  • Rise in healthcare expenditure
  • Increase in environmental pollution

PART 14: Impact of drivers

PART 15: Market challenges

  • Low diagnosis rate
  • Alternative therapies
  • High cost of therapy

PART 16: Impact of drivers and challenges

PART 17: Market trends

  • Rise in awareness programs
  • Increased focus on combination therapies
  • Rise in R&D by global companies

PART 18: Vendor landscape

  • Competitive scenario
  • AstraZeneca
  • Boehringer Ingelheim
  • GSK
  • Merck
  • Novartis
  • Other prominent vendors

PART 19: Appendix

  • List of abbreviations

PART 20: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: China GDP 2010-2014 ($ trillions)
  • Exhibit 03: Healthcare expenditure 2009-2013 (% of GDP)
  • Exhibit 04: Healthcare reforms in China
  • Exhibit 05: Pharmaceutical market in China 2015-2020 ($ billions)
  • Exhibit 06: Some top domestic and international vendors operating in China
  • Exhibit 07: China pharmaceutical market overview: SWOT analysis
  • Exhibit 08: New drug approval (NDA) review process in China
  • Exhibit 09: New drug approval process in China
  • Exhibit 10: Drug registration classification and requirements in China
  • Exhibit 11: Changes in drug pricing system before and after 2015 reforms
  • Exhibit 12: Pipeline portfolio: COPD drugs
  • Exhibit 13: Global respiratory drugs market 2015-2020 ($ billions)
  • Exhibit 14: Global respiratory drugs market shares by type of disease 2015
  • Exhibit 15: Global COPD drugs market 2015-2020 ($ billions)
  • Exhibit 16: Key drivers and challenges in global COPD drugs market
  • Exhibit 17: Global COPD drugs market by class of drugs 2015
  • Exhibit 18: COPD drugs in China in global respiratory drugs market 2015
  • Exhibit 19: COPD drugs market in China 2015-2020 ($ billions)
  • Exhibit 20: Five forces analysis
  • Exhibit 21: Segmentation of COPD drugs based on drug class
  • Exhibit 22: Healthcare spending in China 2004-2014
  • Exhibit 23: Impact of drivers
  • Exhibit 24: Impact of drivers and challenges
  • Exhibit 25: AstraZeneca: YoY revenue and growth rate of Symbicort in China 2014-2015 ($ millions)
  • Exhibit 26: AstraZeneca: YoY revenue and growth rate of Symbicort in emerging markets 2013-2015 ($ millions)
  • Exhibit 27: AstraZeneca: YoY revenue and growth rate of Pulmicort in China 2014-2015 ($ millions)
  • Exhibit 28: AstraZeneca: YoY revenue and growth rate of Pulmicort in emerging markets 2013-2015 ($ millions)
  • Exhibit 29: AstraZeneca: Key takeaways
  • Exhibit 30: Boehringer Ingelheim: Key takeaways
  • Exhibit 31: GSK: YoY revenue and growth rate of Seretide/Advair in international markets 2014-2015 ($ billions)
  • Exhibit 32: GSK: YoY revenue and growth rate of Flixotide/Flovent in international markets 2014-2015 ($ millions)
  • Exhibit 33: GSK: YoY revenue and growth rate of Ventolin in international markets 2014-2015 ($ millions)
  • Exhibit 34: GSK: YoY growth and revenue of Relvar/Breo Ellipta in international markets 2014-2015 ($ millions)
  • Exhibit 35: GSK: Key takeaways
  • Exhibit 36: Merck: Key takeaways
  • Exhibit 37: Novartis: Key takeaways
Back to Top